Brief: Ebglyss Provided Sustained Disease Control For Up To 3 Years In Over 80% Of Adults And Adolescents With Atopic Dermatitis - Almirall
25/09/2024 11:51
Sept 25 (Reuters) - Almirall SA ALM.MC :
* EBGLYSS PROVIDED SUSTAINED DISEASE CONTROL FOR UP TO 3
YEARS IN
OVER 80% OF ADULTS AND ADOLESCENTS WITH MODERATE-TO-SEVERE
ATOPIC DERMATITIS
* SAFETY PROFILE AT THREE YEARS WAS CONSISTENT WITH
PREVIOUSLY
PUBLISHED TWO-YEAR RESULTS
Source text for Eikon: ID:nCNM8Q3nrL
Further company coverage: ALM.MC
(Gdansk Newsroom)
((gdansk.newsroom@thomsonreuters.com; +48 58 769 66 00;))
Recent news on Almirall
See all newsBrief: Almirall Says Phase 3B Adlong Clinical Study Show Treatment Outcomes With Up To Five Years Of Lebrikizumab
Brief: Almirall And CrystalO To Discover, Develop Novel Small Molecules In Medical Dermatology
Almirall shares rise as lower costs beat EBITDA estimates
Brief: Almirall, Certest Biotec Sign Deal to Develop Rare Dermatology Treatments
Spanish stocks - Factors to watch on July 24